EU Decision Imminent On Comirnaty Booster, Data Expected On Use In 5-11 Year Olds
Executive Summary
The European Medicines Agency also expects to reach some conclusions on the use of MAb-based COVID-19 treatments by the end of October.
You may also be interested in...
Coronavirus Notebook: WHO Backs MAb Combo, EMA Assessing Moderna Booster Jab
The COVID Moonshot project has received new funding for the open-source development of new candidate therapeutics, with results expected by the end of the year.
Pfizer COVID Booster Recommendations From CDC Panel Narrower Than FDA's EUA
Advisory Committee on Immunization Practices fails to pass an interim recommendation endorsing third dose of vaccine in health care workers and others at risk of occupational or institutional exposure, with panelists raising concern that the target population was overly broad.
EMA 'Confident' Of New COVID-19 Vaccine Approvals By Year End
The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.